Cargando…

Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review

BACKGROUND: People living in rural and remote communities in Canada are often disproportionately impacted by opioid use disorder. When compared to urban centres, rural and remote populations face additional barriers to treatment, including geographical distance as well as chronic shortages of health...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pijl, Em M., Alraja, Abeer, Duff, Elsie, Cooke, Carol, Dash, Stephen, Nayak, Nichole, Lamoureux, Jesse, Poulin, Ginette, Knight, Erin, Fry, Ben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412807/ https://www.ncbi.nlm.nih.gov/pubmed/36028837 http://dx.doi.org/10.1186/s13011-022-00463-5

Ejemplares similares

The Nurse Practitioner Workforce in Western Canada: A Cross-Sectional Practice Analysis Comparison
por: Duff, E, et al.
Publicado: (2021)

Trends in Rates of Opioid Agonist Treatment and Opioid-Related Deaths for Youths in Ontario, Canada, 2013-2021
por: Rosic, Tea, et al.
Publicado: (2023)

The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada
por: Franklyn, Alexandra M., et al.
Publicado: (2017)

“Guarding their practice”: a descriptive study of Canadian nursing policies and education related to medical cannabis
por: Balneaves, Lynda G., et al.
Publicado: (2019)

Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey
por: Kouyoumdjian, Fiona G., et al.
Publicado: (2018)

Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans
por: Eydt, Erin, et al.
Publicado: (2021)

Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Better agonist for the opioid receptors
por: Badshah, Syed Lal, et al.
Publicado: (2018)

Evidence of Increased Age and Sex Standardized Death Rates Among Individuals Who Accessed Opioid Agonist Treatment Before the Era of Synthetic Opioids in Ontario, Canada
por: Morin, Kristen A, et al.
Publicado: (2021)

Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Characterizing opioid agonist therapy uptake and factors associated with treatment retention among people with HIV in British Columbia, Canada
por: Yazdani, Kiana, et al.
Publicado: (2023)

Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review
por: Rice, Danielle B, et al.
Publicado: (2018)

Alcohol use in opioid agonist treatment
por: Nolan, Seonaid, et al.
Publicado: (2016)

Therapeutic Potential of Kappa Opioid Agonists
por: Beck, Tyler C., et al.
Publicado: (2019)

Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study
por: Russell, Cayley, et al.
Publicado: (2022)

Correction to: Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

Evaluating the effectiveness of concurrent opioid agonist treatment and physician-based mental health services for patients with mental disorders in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2020)

Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework
por: Tahsin, Farah, et al.
Publicado: (2022)

Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015–2018: a repeated cross-sectional analysis
por: Bodkin, Claire, et al.
Publicado: (2021)

Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada
por: Russell, Cayley, et al.
Publicado: (2022)

Access to tablet injectable opioid agonist therapy in rural and smaller urban settings in British Columbia, Canada: a qualitative study
por: Bardwell, Geoff, et al.
Publicado: (2023)

Interim opioid agonist treatment for opioid addiction: a systematic review
por: Samsó Jofra, Laura, et al.
Publicado: (2022)

A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report
por: Crowley, Des, et al.
Publicado: (2020)

A National Needs Assessment of Canadian Nurse Practitioners Regarding Cannabis for Therapeutic Purposes
por: Balneaves, Lynda G., et al.
Publicado: (2018)

Evaluating comparative effectiveness of psychosocial interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analyses
por: Rice, Danielle, et al.
Publicado: (2020)

Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis
por: Garg, Ria, et al.
Publicado: (2022)

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
por: Palis, Heather, et al.
Publicado: (2021)

Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study
por: Morin, Kristen A, et al.
Publicado: (2022)

Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes
por: Day, Nathaniel, et al.
Publicado: (2022)

Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17
por: Yang, Justin C., et al.
Publicado: (2019)

The effect of opioid analgesics, benzodiazepines, gabapentinoids, and opioid agonist treatment on mortality risk among opioid-dependent people.
por: Bharat, Chrianna, et al.
Publicado: (2022)

Changing Pattern of Opioid Users Attending an Opioid Agonist Treatment Clinic in North India
por: Bhat, Fazle R., et al.
Publicado: (2022)

What is the benefit of inconsistent opioid agonist treatment in patients with prescription opioid use disorder?
por: Weiss, R., et al.
Publicado: (2023)

Examining correlations between opioid dispensing and opioid-related hospitalizations in Canada, 2007–2016
por: Jones, Wayne, et al.
Publicado: (2020)

Impact of changes in opioid funding and clinical policies on rapid tapering of opioids in Ontario, Canada
por: Martins, Diana, et al.
Publicado: (2022)

Opioid use in the era of COVID-19: a multifaceted study of the opioid epidemic in Canada
por: Hutchinson, Molly, et al.
Publicado: (2023)

Full Opioid Agonists and Tramadol: Pharmacological and Clinical Considerations
por: Edinoff, Amber N., et al.
Publicado: (2021)

Novel Mixed NOP/Opioid Receptor Peptide Agonists
por: Pacifico, Salvatore, et al.
Publicado: (2021)

In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera
por: Guillemyn, Karel, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3q16cdr3rt3h4hmt6ik91h32u4